EU approves Teizeild for patients with stage 2 type 1 diabetes – Sanofi
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and… read more.
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and… read more.
Diabetes mellitus is a chronic metabolic disorder and one of the most prevalent non-communicable diseases worldwide. On average, one in ten adults is affected. The number of people… read more.
Abbott unveiled Libre Assist, a groundbreaking feature within the Libre app designed to help the millions of people living with diabetes in the U.S. better understand how the foods… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for Mounjaro (tirzepatide). The marketing… read more.
A test using genetics to predict who is at the highest risk of developing type 1 diabetes could one day be applied to largescale health studies, to identify… read more.
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used… read more.
Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to… read more.
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors—such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)—or glucagon-like peptide-1 (GLP-1)… read more.
A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy. The findings appeared… read more.
Medtronic announced the broad U.S. commercial launch of the MiniMed 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed systems. Following U.S…. read more.
Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study emphasises… read more.
Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the United States after internal testing determined that some… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.